



## Positive Quality Intervention: Tisotumab vedotin-tftv (Tivdak®) Management

**Description:** Tisotumab vedotin-tftv is FDA approved for treatment of recurrent or metastatic cervical cancer in patients with disease progression on or after chemotherapy. This PQI will provide information on the management of common adverse events and follow-up required for these.

**Background:** Tisotumab vedotin-tftv is first in class antibody drug conjugate that contains a humanized IgG1-kappa monoclonal antibody directed at tissue factor and is conjugated to a microtubule-disrupting agent (monomethyl auristatin E or MMAE) via a protease-cleavable linker. After binding to tissue factor, tisotumab vedotin is internalized and releases MMAE via proteolytic cleavage resulting in microtubule disruption and cell death. Tisotumab vedotin-tftv's FDA approval for recurrent or metastatic cervical cancer was based on the innovaTV 204 clinical trial showing 24% objective response rates and 72% disease control rate.<sup>3</sup> The recommended dose is 2 mg/kg with a maximum dose of 200 mg for patients with weight greater than 100 kg. The median overall survival was 12.1 months and median duration of response was 8.3 months. The most common treatment related adverse events with incidence ranging from 23% to 38% included alopecia, epistaxis, nausea, conjunctivitis, fatigue, and dry eye. The incidence of grade 3 or worse adverse events was 28% or seen in 28 patients out of 101 patients. These included neutropenia, fatigue, ulcerative keratitis, and peripheral neuropathies. Due to the increased incidence of eye toxicities, patients who will be on therapy with tisotumab vedotin-tftv require multiple eye drops, cooling of eyes during infusion, and eye exam prior to each and every dose. Treatment related bleeding events occurred in 39% of patients, including 30% of patients who experienced epistaxis. Patients should be monitored closely for bleeding events.

**PQI Process:** Upon receiving order of tisotumab vedotin-tftv for administration:

- Confirm appropriateness for the specific patient utilizing pertinent information from the EMR
- Ensure that the patient has had an eye exam prior to treatment and has been sent eye drop prescriptions (Table 2)
- Check with the nurse that the patient has brought all the eye drops to the clinic and appropriate eye cooling patch or pads are available in clinic for patient to cool the eyes
  - Many practices are using ice packs with a barrier (to keep condensation from dripping into the patient's eye) when cooling pad are unavailable \*not recommended by the manufacturer\*
- Review the order for any specific dose adjustment if needed (Table 1)
- Drug interaction consideration: close follow up of patients who are on concomitant strong CYP3A4 inhibitors is required as strong CYP3A4 inhibitors may increase unconjugated MMAE exposure; this in turn may increase the risk of tisotumab vedotin-tftv adverse events
- Review adverse events (AE) and management as required (Table 3)

### Patient Centered Activities:

- Patient Education
  - Provide eyecare guide sheet from [Tivdak® website](#)
  - Educate and explain how to administer various eye drops and provide a checklist for patients to remind them about dosing of their eye drops
  - Ensure patient understands the importance of an eye exam prior to each dose
    - Assist patients to schedule these exams

**Important notice:** NCODA has developed this Positive Quality Intervention platform. This platform represents a brief summary of medication uses and therapy options derived from information provided by the drug manufacturer and other resources. This platform is intended as an educational aid and does not provide individual medical advice and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication discussed in the platform and is not intended as a substitute for the advice of a qualified healthcare professional. The materials contained in this platform are for informational purposes only and do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA, which assumes no liability for and does not ensure the accuracy of the information presented. NCODA does not make any representations with respect to the medications whatsoever, and any and all decisions, with respect to such medications, are at the sole risk of the individual consuming the medication. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional. Updated 6.28.22



- Encourage patients to report any eye problems (dry eye, blurry vision, irritation, redness)
  - Educate the patient on when to contact the care team and adverse events that should be reported to the care team:
    - Fever of 100.4° F
    - Unusual bleeding (ex. nose bleeds that will not stop, bruises, vaginal bleeding)
    - Black/tarry stools or bloody urine
    - Tingling in fingers and toes
    - Nausea/vomiting/diarrhea
    - Shortness of breath
  - Encourage patients to report any new medications started by other providers

**References:**

1. [Tivdak \(tisotumab vedotin\) \[prescribing information\]](#).
2. Hong DS, Concin N, Vergote I, et al. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer. Clin Cancer Res. 2020;26(6):1220-8.
3. Coleman RL, Lorusso D, Gennigens C, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(5):609-19.

**Supplemental Information:**

**Table 1: Dose Modifications:**

Starting Dose	2 mg/kg
First Dose Reduction	1.3 mg/kg
Second Dose Reduction	0.9 mg/kg
Third Dose Reduction	Permanently Discontinue

**Table 2: Eye Care Requirements**

<b>Ophthalmic Exam - including visual acuity and slit lamp exam</b>	Prior to starting treatment and prior to each dose.
<b>Topical corticosteroids eye drops</b>	Administer 1 drop in each eye 10 minutes prior to infusion and continue for additional 2 times at home on day 1. Continue 1 drop per eye 3x per day on days 2 and 3 after infusion as well.
<b>Topical ocular vasoconstrictor eye drops</b>	Administer 3 drops in each eye 10 minutes prior to infusion.
<b>Topical lubricating eye drops</b>	Administer 1 drop in each eye daily for the duration of therapy and for 30 days after the last dose of therapy. However, Eye care providers may prescribe different frequency of lubricating eye drops due to baseline eye exam.
<b>Cooling eye packs/pads</b>	Start cooling the eyes ~ 10 mins prior to infusion and continuing for a total of 60 minutes. Rotate cooling pads as needed.
<b>Contact Lens</b>	Patients should be instructed to avoid wearing contact lens throughout therapy.

**Important notice:** NCODA has developed this Positive Quality Intervention platform. This platform represents a brief summary of medication uses and therapy options derived from information provided by the drug manufacturer and other resources. This platform is intended as an educational aid and does not provide individual medical advice and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication discussed in the platform and is not intended as a substitute for the advice of a qualified healthcare professional. The materials contained in this platform are for informational purposes only and do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA, which assumes no liability for and does not ensure the accuracy of the information presented. NCODA does not make any representations with respect to the medications whatsoever, and any and all decisions, with respect to such medications, are at the sole risk of the individual consuming the medication. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional. Updated 6.28.22



**Table 3: Adverse events and management**

Adverse Event	Severity/Grade	Dose Modification
<b>Keratitis</b>	Superficial punctate keratitis (SPK) (any occurrence)	Monitor
	Confluent superficial keratitis (first occurrence)	Hold until it improves to SPK or normal, then resume at next lower dose
	Confluent superficial keratitis (second occurrence)	Permanently discontinue
	Ulcerative keratitis or perforation (any occurrence)	Permanently discontinue
<b>Conjunctival Ulceration</b>	Any ulceration (first occurrence)	Hold until normal, then resume treatment at next lower dose
	Any ulceration (second occurrence) + scarring or symblepharon (any occurrence)	Permanently discontinue
<b>Conjunctivitis and other ocular AE</b>	Grade 1 (any occurrence)	Monitor
	Grade 2 (first occurrence)	Hold until Grade $\leq 1$ ; resume at same dose
	Grade 2 (second occurrence)	Hold until Grade $\leq 1$ ; resume at next lower dose
	Grade 2 (third occurrence) or Grade 3 or 4 (any occurrence)	Permanently discontinue
<b>Peripheral Neuropathy</b>	Grade 2 initial or worsening of pre-existing (any occurrence)	Hold until Grade $\leq 1$ ; resume at next lower dose
	Grade 3 or 4 (any occurrence)	Permanently discontinue
<b>Hemorrhage</b>	Any grade pulmonary or CNS (any occurrence) OR Grade 3 in any other location (second occurrence) OR Grade 4 in any other location	Permanently discontinue
	Grade 2 in any other location (any occurrence) or Grade 3 in any other location (first occurrence)	Hold until resolved, resume at same dose
<b>Pneumonitis</b>	Grade 2 (any occurrence)	Hold until Grade $\leq 1$ for persistent or recurring pneumonitis; consider resuming at next dose
	Grade 3 or 4 (any occurrence)	Permanently discontinue

**Important notice:** NCODA has developed this Positive Quality Intervention platform. This platform represents a brief summary of medication uses and therapy options derived from information provided by the drug manufacturer and other resources. This platform is intended as an educational aid and does not provide individual medical advice and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication discussed in the platform and is not intended as a substitute for the advice of a qualified healthcare professional. The materials contained in this platform are for informational purposes only and do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA, which assumes no liability for and does not ensure the accuracy of the information presented. NCODA does not make any representations with respect to the medications whatsoever, and any and all decisions, with respect to such medications, are at the sole risk of the individual consuming the medication. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional. Updated 6.28.22